Journal article
Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9).
Abstract
22 Background: Metastases directed therapy (MDT) in metachronous hormone sensitive prostate cancer (mHSPS) patients has been shown to delay systemic therapy and to a lesser extent improve oncological outcome. To date there has not been strong data to suggest benefit of MDT in castration resistant prostate cancer (CRPC). In this multi-centric randomized phase II trial, we sought to determine the benefit of stereotactic body radiotherapy (SBRT) …
Authors
Niazi T; Saad F; Koul R; Thibault I; Chung PWM; Wakil G; Lock M; Delouya G; Bahoric B; Feifer A
Journal
Journal of Clinical Oncology, Vol. 43, No. 5_suppl, pp. 22–22
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 10, 2025
DOI
10.1200/jco.2025.43.5_suppl.22
ISSN
0732-183X